singl
infecti
rout
use
virus
human
viral
infect
transmiss
occur
multipl
path
fecalor
ingest
contamin
food
drink
sexual
contact
exposur
infect
blood
exchang
saliva
aerosol
gener
sneez
cough
common
exampl
virus
isol
oral
caviti
includ
rotaviru
noroviru
hiv
hepat
c
viru
herp
simplex
virus
epsteinbarr
viru
influenza
virus
influenza
common
cold
virus
among
frequent
type
human
viral
infect
common
cold
gener
life
threaten
usual
resolv
without
medic
intervent
caus
group
highli
contagi
airborn
virus
vaccin
avail
best
protect
avoid
close
proxim
individu
infect
contrast
influenza
result
mani
fatal
particularli
elderli
individu
suppress
immun
system
annual
modifi
influenza
vaccin
avail
western
world
initi
offer
individu
risk
avail
everyon
howev
note
influenza
vaccin
effect
among
peopl
receiv
influenza
vaccin
prior
year
comparison
vaccin
effect
among
get
influenza
vaccin
previou
year
substanti
lower
occasion
new
influenza
variant
may
caus
pandem
result
zoonosi
ie
transmiss
anim
flu
viru
human
genet
recombin
precis
reassort
gene
segment
human
viru
nonhuman
form
cross
speci
wellknown
recent
exampl
swine
flu
avian
bird
flu
sometim
confus
zoonot
sever
acut
respiratori
syndrom
viru
corona
viru
worldwid
polici
reduc
elimin
risk
epidem
success
sever
infecti
diseas
larg
erad
control
western
world
result
nation
vaccin
program
success
exampl
humandriven
erad
smallpox
viru
follow
implement
worldwid
vaccin
strategi
approach
succeed
smallpox
viru
variola
essenti
compris
singl
strain
anim
vector
approach
measl
anoth
exampl
demonstr
success
vaccin
measl
highli
contagi
infect
respiratori
system
spread
aerosol
transmiss
contact
nasal
oral
fluid
effect
vaccin
avail
usa
measl
declar
elimin
world
health
assembl
global
goal
propos
elimin
diseas
target
reduct
mortal
unfortun
recent
measl
outbreak
usa
case
mostli
unvaccin
individu
wwwcdcgovmeasl
result
new
vaccin
vaccin
polici
also
improv
medic
care
develop
novel
drug
worldwid
infecti
diseas
fatal
increas
past
two
decad
howev
signific
decreas
worldwid
expect
equival
western
world
resourc
becom
avail
resourcepoor
area
global
approach
erad
polio
anoth
exampl
current
world
popul
live
poliofre
region
collabor
strateg
endgam
plan
place
erad
last
reservoir
polio
global
polio
erad
initi
list
viral
infect
viral
diseas
extens
erad
one
pathogen
may
provid
nich
anoth
pathogen
becom
virul
natur
acquir
immun
exposur
pathogen
like
provid
best
protect
recur
infect
presenc
viabl
viru
oral
fluid
specimen
typic
demonstr
screen
viral
nucleic
acid
initi
viral
nucleic
acid
isol
oral
fluid
sampl
directli
centrifug
perform
concentr
cellassoci
viru
usual
follow
pcr
amplif
virusspecif
viral
nucleic
acid
fragment
use
signal
amplif
technolog
hiv
viralload
analysi
frequent
use
commerci
assay
base
viral
nucleic
acid
amplif
coba
amplicor
monitor
test
roch
diagnost
indianapoli
usa
exampl
commerci
assay
base
signal
amplif
versant
rna
assay
siemen
ag
munich
germani
viral
nucleic
acidbas
method
sensit
consid
less
contagi
pathogen
sampl
inactiv
initi
viral
nucleic
acid
isol
protocol
howev
amplificationbas
detect
viral
nucleic
acid
rel
expens
requir
train
personnel
specif
equip
may
alway
proof
activ
infect
ultim
cultiv
confirmatori
test
may
need
obtain
definit
diagnosi
detect
viral
antigen
indirect
fluoresc
antibodi
label
electron
microscop
techniqu
use
detect
presenc
intact
viral
particl
note
presenc
microscop
intact
viral
particl
specif
biolog
fluidmatrix
distinguish
viableinfecti
viru
noninfecti
viru
list
exampl
viabl
virus
detect
oral
fluid
sampl
provid
tabl
contrast
serum
plasma
standard
protocol
salivaor
fluid
collect
thu
saliva
may
refer
wholemouth
stimul
unstimul
saliva
sampl
obtain
oral
swab
brush
filter
centrifug
saliva
use
detect
free
viru
viru
may
free
cellbound
use
whole
saliva
oral
swab
virus
easili
cultiv
contrast
bacteria
directli
grown
cultur
media
requir
specif
live
cell
support
replic
human
papillomaviru
hepat
c
viru
herp
simplex
viru
human
herpesviru
coronavirus
rhinovirus
exampl
virus
known
difficult
cultur
determin
presenc
viabl
viru
oral
fluid
sampl
alway
indic
viru
transmit
oral
case
cytomegaloviru
member
herpesvirida
famili
known
transmiss
occur
via
direct
contact
bodi
fluid
although
serolog
suggest
preval
cytomegaloviru
blood
donor
routin
test
activ
cytomegaloviru
infect
viru
blood
cell
associ
leucocytedeplet
redbloodcel
product
consid
cytomegaloviru
safe
howev
situat
saliva
probabl
differ
cytomegaloviru
transmiss
rout
saliva
similar
follow
infect
epsteinbarr
viru
herpesvirida
member
respons
caus
infecti
mononucleosi
kiss
diseas
oral
hairi
leukoplakia
contrast
mani
studi
focus
hiv
describ
inactiv
viru
salivari
compon
indic
likelihood
transmit
hiv
saliva
extrem
low
report
mention
isol
viabl
hiv
oral
fluid
sampl
analysi
infect
saliva
sampl
show
lack
specif
antihiv
immunoglobulin
nonspecif
antivir
activ
addit
report
human
virus
studi
describ
presenc
viabl
plant
pathogen
human
oral
sampl
exampl
tobacco
mosaic
viru
identifi
sputum
sampl
smoker
although
specul
associ
plant
viru
specif
communic
diseas
establish
recent
exampl
demonstr
viral
nucleic
acid
oral
caviti
amplif
specif
viral
nucleic
acid
fragment
shown
tabl
besid
current
wide
util
viral
nucleic
acidbas
detect
method
immunologicbas
diagnost
pathogenderiv
antigen
also
use
demonstr
activ
infect
exampl
detect
hepat
b
surfac
antigen
common
test
amen
salivari
diagnosi
hepat
b
viru
antigen
assay
demonstr
activ
viral
infect
use
oral
sampl
describ
ebola
rabi
hiv
pathogenderiv
antigen
eg
hiv
often
present
higher
level
viral
genom
identifi
abund
viral
protein
copi
per
nucleic
acid
amplif
compat
simultan
screen
detect
multipl
pathogen
singl
sampl
use
multipl
pair
dna
primer
specif
target
microorgan
develop
fulli
integr
rapid
test
devic
capabl
analyz
clinic
sampl
panel
specif
pathogen
target
would
great
valu
pointofcar
use
devic
feasibl
current
avail
viral
nucleic
acidamplif
technolog
howev
cost
sampleprepar
issu
still
need
address
recent
technolog
advanc
allow
analysi
deep
sequenc
human
salivari
microbiom
creat
catalog
microorgan
present
saliva
oral
mucosa
analysi
salivari
virom
viru
subset
salivari
microbiom
demonstr
major
oral
virus
bacteriophag
postul
phage
requir
bacteri
cell
replic
probabl
play
import
role
microbi
divers
health
oral
caviti
may
also
influenc
suscept
human
viral
infect
optim
oral
fluid
viral
nucleic
acidisol
method
combin
avail
highthroughput
sequenc
analysi
technolog
provid
use
tool
identifi
known
well
unknown
virus
although
wide
util
immunolog
detect
activ
infect
report
infect
hiv
exampl
dengu
virusspecif
iga
serum
saliva
detect
soon
infect
dengueendem
region
moreov
denguespecif
igmigg
level
may
use
distinguish
primari
secondari
infect
howev
antibodi
test
tabl
alway
detect
activ
infect
valid
document
exposur
uncommon
virus
west
nile
viru
antibodi
test
also
use
blooddonor
screen
identifi
individu
expos
human
tlymphotrop
viru
ii
hepat
virus
b
c
rapid
diagnosi
need
identifi
pathogen
clinician
would
like
determin
acut
infect
bacteri
viral
origin
contrast
system
diseas
display
multipl
biomark
detect
singl
pathogenspecif
target
diagnos
diseaseinfect
current
definit
test
distinguish
viral
bacteri
infect
test
possibl
pathogen
andor
biomark
use
microarray
technolog
blood
saliva
bacteri
infect
ideal
treat
narrowrang
antibiot
bacteri
pathogen
identifi
howev
broadrang
antibiot
typic
use
identif
avail
owe
emerg
antibioticresist
strain
pathogen
antibiogram
determin
suscept
pathogen
varieti
antibiot
increasingli
requir
test
carri
clinic
microbiolog
laboratori
may
take
hour
day
appropri
inform
avail
select
best
therapi
treatment
specif
infect
acut
viral
infect
easili
resolv
drug
requir
differ
approach
misdiagnosi
bacteri
infect
viral
infect
fatal
consequ
case
bacteri
mening
vs
viral
mening
acut
infect
type
pathogen
establish
antibiot
often
prescrib
precautionari
measur
howev
highdos
antibiot
acut
bacteri
mening
toxic
lead
allerg
reaction
laboratorybas
test
identifi
pathogen
may
requir
sever
hour
day
obtain
result
rapid
pointofcar
test
provid
immedi
result
desir
could
immedi
determin
appropri
treatment
case
emerg
major
issu
sampl
assay
result
time
saliva
fingerstick
blood
test
util
pointofcar
test
lessacut
situat
saliva
biolog
matrix
pointofcar
diagnosi
well
accept
patient
prefer
choos
fingerstick
blood
oral
sampl
moreov
use
oral
sampl
ideal
nonhospit
set
local
physician
offic
small
commun
health
facil
dental
offic
first
respond
home
care
studi
report
use
oral
sampl
altern
blood
urin
sampl
detect
pathogenspecif
antigen
antibodi
nucleic
acid
gener
concentr
target
molecul
saliva
lower
amplif
technolog
facilit
identif
viral
marker
use
saliva
sampl
replac
lumbar
punctur
obtain
sampl
unequivoc
identifi
pathogen
caus
acut
mening
would
ideal
yet
avail
specif
biomolecul
deriv
viru
circul
bloodstream
present
mucosa
like
present
also
oral
sampl
detect
human
antibodi
measl
mump
oral
fluid
first
describ
three
decad
ago
sinc
sever
simpl
platform
antibodi
detect
saliva
oral
mucos
transud
publish
antibodi
test
wide
use
diagnosi
infecti
diseas
presenc
antibodi
discrimin
past
current
infect
residu
antibodi
present
circul
result
previou
immun
howev
fourfold
increas
antibodi
titer
convalesc
may
aid
identif
particular
pathogen
requir
accur
quantit
antibodi
assay
wherea
exist
rapid
antibodi
assay
qualit
provid
yesno
answer
contrast
hiv
antibodi
test
use
establish
hivposit
statu
infect
selfclear
cure
vaccin
current
avail
therefor
presenc
antihiv
immunoglobulin
use
screen
test
howev
antibodi
presenc
correl
viral
load
abil
transmit
diseas
hivinfect
patient
antivir
therapi
antibodi
posit
may
viral
load
level
detect
fdaapprov
saliva
antibodi
test
avail
overthecount
home
test
concern
regard
test
individu
suspect
exposur
hiv
may
use
earli
postexposur
result
receiv
falseneg
test
result
take
week
longer
mount
antibodi
respons
time
period
refer
seroconvers
window
situat
pose
potenti
risk
newli
infect
individu
period
seroconvers
extrem
high
viral
load
thu
highli
contagi
report
indic
salivabas
test
lower
clinic
sensit
bloodbas
test
may
case
includ
hivinfect
individu
receiv
highli
activ
antiretrovir
therapi
haart
extend
period
review
summar
unpublish
result
two
studi
demonstr
level
antibodi
saliva
differ
level
blood
although
antibodi
level
blood
saliva
hivinfect
individu
differ
significantli
seroposit
result
identifi
use
either
blood
saliva
test
fluid
elabor
laboratorybas
test
eg
full
analysi
blood
necessari
provid
quantit
result
rapid
antibodi
test
provid
qualit
result
saliva
prefer
sampl
blood
higher
patient
accept
issu
safeti
chanc
injuri
caus
needl
cost
eg
requir
phlebotomist
compat
selftest
eventu
oral
sampl
may
provid
ideal
matrix
diagnos
mani
viral
infect
current
two
oralbas
commerci
test
infecti
diseas
fda
approv
use
usa
oraquick
oral
hiv
test
orarisk
human
papillomaviru
salivari
diagnost
test
oraquick
test
orasur
technolog
inc
bethlehem
pa
usa
fdaapprov
clia
wave
test
use
oral
swab
specimen
orarisk
human
papillomaviru
test
oraldna
lab
access
genet
llc
also
fda
approv
util
oral
fluid
sampl
sent
central
laboratori
nucleic
acid
analysi
oraquick
recent
approv
overthecount
homeus
test
take
min
sampl
collect
result
visual
line
test
strip
platform
use
develop
commerci
oral
hepat
c
viru
test
although
antibodi
assay
gener
unequivoc
diagnos
activ
viral
infect
valuabl
tool
track
exposur
pathogen
antibodi
screen
use
epidemiolog
studi
monitor
larg
popul
immun
common
viral
infect
wherea
screen
young
children
presenc
antibodi
infecti
agent
thought
elimin
use
monitor
potenti
reemerg
pathogen
use
saliva
clinic
sampl
largescal
approach
costeffect
sampl
collect
noninvas
particip
home
mail
nation
test
laboratori
wide
accept
antibodi
detect
blood
also
detect
saliva
howev
fluctuat
differ
concentr
salivari
flow
rate
vari
circadian
rhythm
saliva
composit
variabl
bloodplasma
moreov
antibodi
isotyp
differ
salivari
gland
produc
secret
salivari
iga
wherea
igg
igm
enter
oral
caviti
leakag
bloodstream
gingiv
crevicular
fluid
present
lower
concentr
anoth
issu
studi
util
oral
sampl
method
collect
exampl
respect
antibodi
type
composit
whole
saliva
quit
differ
composit
gingiv
crevicular
fluid
transud
close
resembl
blood
antibodi
detect
consequ
high
abund
seroconvers
collect
method
less
critic
case
target
pathogenderiv
analyt
nucleic
acid
previou
studi
explor
develop
modular
microfluid
test
devic
multiplex
analysi
saliva
sampl
versatil
gener
antibodi
assay
fig
evalu
use
two
set
saliva
sampl
collect
use
differ
protocol
set
wih
obtain
woman
interag
hiv
studi
compris
sampl
upon
collect
immedi
store
preserv
wherea
set
sampl
collect
studi
fund
nation
institut
dental
craniofaci
research
nih
grant
compris
sampl
upon
collect
clarifi
use
salivacollect
spong
uplink
collector
set
pair
serum
saliva
sampl
test
parallel
valid
saliva
result
figur
show
result
obtain
wih
fig
sampl
fig
assay
result
present
normal
valu
ratio
signal
measur
test
line
divid
signal
measur
flow
control
line
assay
cutoff
threshold
valu
sampl
design
reactiv
determin
averag
valu
obtain
hivneg
control
sampl
hivposit
sampl
uniformli
gener
higher
assay
valu
hivneg
sampl
appar
independ
salivacollect
protocol
similar
pattern
compar
saliva
bloodantibodi
level
also
observ
infecti
diseas
saliva
play
key
role
protect
bodi
wide
varieti
viral
infect
addit
role
control
colon
bacteria
oral
caviti
mani
biomolecul
saliva
antivir
activ
specif
virus
viral
infect
occur
across
mucos
membran
mouth
eye
common
site
viral
entri
although
viral
infect
eye
oral
caviti
rel
rare
mechan
viral
infect
control
includ
mani
biomolecul
includ
mucin
antibodi
antivir
protein
present
continu
flow
fluid
interest
mani
antivir
molecul
present
saliva
tear
hypoton
saliva
capabl
lyse
envelop
virus
respons
infect
involv
complex
highli
regul
process
innat
immun
system
first
nonspecif
defens
bacteria
virus
specif
respons
includ
cellmedi
immun
adapt
immun
system
increas
cytokin
level
thelper
cell
product
antipathogenspecif
antibodi
pathogen
antigen
secondari
respons
involv
reservoir
specif
memori
cell
permit
faster
respons
recur
infect
pathogen
presenc
specif
antibodi
specif
cytokin
respons
mononuclear
blood
cell
pathogenspecif
antigen
use
diagnost
tool
distinguish
activ
latent
infect
confirm
monitor
activ
infect
gener
requir
detect
pathogenspecif
antigen
nucleic
acid
cultiv
pathogen
gateway
gastrointestin
tract
antivir
activ
present
oral
caviti
may
also
prevent
virus
reach
lower
portion
gastrointestin
tract
mucin
present
saliva
product
along
entir
gastrointestin
tract
serv
trap
bacteria
virus
prevent
colon
epitheli
surfac
coat
group
molecul
deriv
innat
immun
system
eg
lysozym
lactoferrin
lactoperoxidas
secretori
leukocyt
proteas
inhibitor
defensin
also
present
tear
saliva
consid
vast
array
pathogen
human
expos
daili
basi
level
infect
surprisingli
low
indic
hostderiv
protect
mechan
remark
job
bacteri
viral
control
whilst
mani
host
factor
pathogen
present
uniqu
mode
infect
uniqu
mean
host
control
infect
typic
viru
enter
cell
attach
specif
receptor
cell
surfac
case
hiv
viru
bind
coreceptor
rabi
viru
attach
neural
cell
adhes
molecul
receptor
whilst
herp
simplex
viru
util
number
cellular
receptor
includ
tolllik
receptor
epsteinbarr
viru
respons
infecti
mononucleosi
oral
hairi
leukoplakia
appear
enter
cell
util
multipl
viral
surfac
protein
multipl
cell
receptor
may
increas
oral
transmiss
effici
noroviru
major
caus
gastroenter
bind
blood
group
antigen
present
red
blood
cell
saliva
secretorposit
individu
note
popul
secret
blood
type
antigen
saliva
next
section
focu
number
viral
infect
detect
oral
fluid
protect
role
saliva
target
mechan
involv
infect
pathway
tabl
noroviru
refer
famili
rna
nonenvelop
virus
major
caus
nonbacteri
gastroenter
transmit
fecalor
rout
follow
exposur
fecalcontamin
fomit
food
water
possibl
also
direct
personperson
contact
shellfish
grown
contamin
water
contrast
noroviru
rabi
viru
usual
transmit
via
saliva
follow
bite
infect
anim
result
enceph
suggest
spelunk
may
becom
infect
inhal
aerosol
bat
coloni
hang
upsid
cave
diseas
preval
area
endem
dog
rabi
infect
bat
viru
bind
nicotin
receptor
muscl
fiber
newli
infect
anim
migrat
via
nerv
brain
replic
spread
via
neuron
rout
salivari
gland
ultim
appear
saliva
rabiesinfect
anim
bite
human
spread
central
nervou
system
subsequ
viru
found
saliva
human
host
rabi
antigen
antibodi
detect
saliva
infect
anim
human
typic
late
infect
make
serolog
detect
littl
practic
valu
pcr
detect
rabi
viru
saliva
report
appropri
preexposur
vaccin
postexposur
prophylaxi
rabi
immun
globulin
vaccin
effect
earli
treatment
along
antivir
drug
otherwis
diseas
typic
fatal
massiv
anim
control
preexposur
vaccin
made
rabiesrel
mortal
usa
rel
rare
fewer
two
death
per
year
human
papillomavirus
famili
dna
virus
infect
epitheli
cell
skin
mucosa
differ
strain
human
papillomaviru
abl
infect
genit
reproduct
tract
oral
caviti
caus
wart
predominantli
hand
feet
usa
human
papillomaviru
infect
lifetim
clear
without
caus
diseas
antibodi
test
screen
potenti
activ
human
papillomaviru
infect
therefor
consid
relev
twelv
strain
human
papillomaviru
consid
high
risk
mean
lead
cancer
primarili
cervic
oral
cancer
human
papillomaviru
strain
two
highrisk
strain
frequent
associ
cancer
premalign
condit
cervic
cancer
attribut
two
strain
howev
beachler
et
al
studi
individu
found
preval
oral
strain
human
papillomavirus
human
papillomaviru
strain
includ
nation
prevent
program
includ
administr
antihuman
papillomaviru
vaccin
oral
human
papillomaviru
infect
higher
preval
hivinfect
individu
uninfect
hiv
individu
result
higher
risk
develop
human
papillomavirusassoci
cancer
particularli
head
neck
cancer
interest
case
studi
two
coupl
human
papillomavirusassoci
tonsillar
carcinoma
human
papillomaviru
strain
ident
partner
suggest
possibl
infecti
natur
oropharyng
cancer
present
oraldna
lab
access
genet
llc
commerci
avail
salivari
diagnost
test
human
papillomaviru
oral
sampl
collect
swab
place
transport
media
sent
central
laboratori
nucleic
acidbas
human
papillomaviru
detect
strain
identif
salivari
test
orarisk
human
papillomaviru
identifi
sever
human
papillomaviru
type
focu
human
human
type
commonli
link
oral
cancer
epsteinbarr
viru
member
herpesvirida
famili
dna
virus
known
caus
diseas
human
lymphocryptoviru
target
bcell
epitheli
cell
also
refer
human
herpesviru
oral
transmit
viru
one
common
virus
worldwid
infect
rate
adult
popul
although
exposur
viru
high
primari
infect
asymptomat
howev
longterm
carriag
associ
epithelialcel
malign
includ
nasopharyng
carcinoma
oral
hairi
leukoplakia
may
play
role
mani
benign
malign
diseas
epsteinbarr
viru
spread
sexual
contact
blood
transfus
organ
transplant
howev
frequent
transmiss
thought
occur
saliva
viru
surviv
object
surfac
long
stay
moist
thu
easili
transmit
eg
share
drink
vaccin
avail
prevent
infect
epsteinbarr
viru
caus
major
infecti
mononucleosi
case
also
known
pfeiffer
kiss
diseas
common
among
young
adult
teenag
infect
may
caus
fatigu
malais
may
take
sever
month
recov
clinic
symptom
indic
mononucleosislik
symptom
infecti
mononucleosi
confirm
presenc
atyp
lymphocyt
serolog
test
past
serolog
diagnost
test
detect
presenc
heterophil
antibodi
weak
antibodi
multispecif
activ
poorli
defin
antigen
epidemiolog
studi
use
detect
specif
antibodi
saliva
determin
popul
immun
report
current
sensit
igg
reflect
past
infect
igm
reflect
current
infect
diagnost
develop
reduc
falseneg
rate
thu
rule
infecti
mononucleosi
previous
presenc
infecti
epsteinbarr
viru
saliva
demonstr
abil
saliva
extract
transform
lymphocyt
cultur
nucleic
acidbas
detect
sensit
standard
method
detect
infect
herp
simplex
viru
doublestrand
dna
viru
enter
cell
interact
viral
coat
glycoprotein
cellular
receptor
viral
capsid
eventu
transport
cell
nucleu
dna
releas
nucleu
replic
initi
linear
viral
dna
integr
human
genom
remain
extrachromosom
circular
dna
viral
episom
oncogen
virus
herpesvirida
famili
includ
epsteinbarr
viru
report
integr
low
frequenc
host
chromosom
associ
herp
simplex
epsteinbarr
viru
aggress
periodont
diseas
report
suggest
possibl
virus
interact
bacteria
link
periodont
diseas
herp
simplex
viru
herp
simplex
viru
two
member
herpesvirida
famili
highli
contagi
spread
easili
period
shed
shed
period
recogn
individu
moist
blister
mucou
membran
lip
mouth
genit
cold
sore
frequent
lip
wellrecogn
sign
herp
simplex
viru
infect
salivari
contact
well
share
drink
food
avoid
prevent
transmiss
viru
herp
simplex
viru
infect
common
sexual
transmit
diseas
gener
refer
genit
herp
although
herp
simplex
viru
herp
simplex
viru
detect
oral
genit
infect
herp
simplex
viru
neurotrop
viru
capabl
infect
nerv
cell
thu
avoid
human
immun
respons
activ
infect
period
shed
viru
becom
latent
remain
neural
ganglia
reactiv
viru
occur
period
stress
fatigu
ill
viru
transport
nerv
cell
axon
epithelium
viru
replic
shed
occur
herp
simplex
viru
infect
selfcur
remain
lifelong
latent
infect
may
lead
recurr
infect
although
antivir
drug
may
reduc
sever
reactiv
decreas
chanc
transmiss
herp
infect
neonat
becom
life
threaten
viru
spread
central
nervou
system
caus
mening
enceph
antivir
medic
may
recommend
pregnant
woman
infect
herp
simplex
viru
current
vaccin
approv
herp
simplex
viru
sever
studi
mainli
focus
vaccin
genit
herp
herp
simplex
viru
ongo
carrier
viru
know
infect
report
link
herp
simplex
viru
infect
virus
herpesvirida
famili
increas
risk
develop
alzheim
diseas
confirm
may
chang
focu
herp
simplex
viru
research
although
herp
simplex
viru
infect
widespread
routin
test
herp
simplex
viru
recommend
benefit
test
clear
diseas
cure
vaccin
avail
question
would
lead
effect
reduct
transmiss
test
cost
effici
also
relat
fals
posit
test
result
confirmatori
test
remain
unansw
diagnost
laboratori
test
fact
recommend
peopl
show
symptom
activ
infect
order
confirm
diagnosi
typic
herp
simplex
viru
infect
consid
link
recurr
genit
herp
half
firstepisod
case
actual
caus
herp
simplex
viru
recommend
laboratori
test
includ
serolog
test
well
virolog
test
viral
cultur
lesion
viral
cultur
may
take
day
futur
might
replac
accur
nucleic
acid
test
use
pcr
sever
studi
describ
detect
antiherp
simplex
viru
antibodi
nucleic
acid
oral
sampl
antibodi
test
specif
type
herp
simplex
viru
like
nucleic
acid
test
distinguish
herp
simplex
viru
herp
simplex
viru
one
first
report
show
presenc
herp
simplex
viru
iga
antibodi
saliva
publish
demonstr
elev
herp
simplex
viru
iga
level
patient
peptic
ulcer
current
dogma
herp
simplex
viru
frequent
found
upper
gastrointestin
tract
ulcer
normal
gastric
duoden
mucosa
ulcer
link
infect
helicobact
pylori
iga
present
saliva
block
infect
herp
simplex
viru
demonstr
vitro
effici
viral
neutral
vivo
still
unknown
viabl
herp
simplex
viru
isol
saliva
current
method
util
viral
nucleic
acid
detect
although
quantit
measur
infecti
virion
tateishi
et
al
demonstr
nucleic
acid
detect
sensit
method
determin
herp
simplex
viru
infect
rapid
antibodi
test
develop
use
blood
sampl
modifi
exist
rapid
test
detect
antibodi
oral
fluid
would
appear
straightforward
overthecount
rapid
test
would
primarili
serv
reassur
individu
absenc
herp
simplex
viru
infect
whether
rapid
test
base
detect
viral
antigen
viral
nucleic
acid
saliva
would
use
matter
debat
local
sampl
lesion
diagnosi
genit
herp
avail
situat
viral
infect
hepat
c
viru
hiv
clearli
differ
see
common
hepatotrop
virus
caus
viral
hepat
hepat
virus
ae
although
name
suggest
similar
virus
relat
differ
properti
hepat
viru
instanc
replic
individu
alreadi
infect
hepat
b
viru
vaccin
avail
prevent
infect
hepat
type
b
e
although
avail
global
vaccin
avail
hepat
c
viru
accord
us
center
diseas
control
prevent
common
chronic
bloodborn
infect
usa
current
result
mortal
hiv
europ
preval
hepat
c
viru
vari
northern
europ
finland
eastern
europ
romania
core
current
hepat
c
viru
epidem
attribut
inject
drug
use
contamin
needl
transmiss
sexual
contact
mothertochild
occur
much
lower
frequenc
fact
hepat
c
viru
transmiss
follow
similar
rout
hiv
risk
transmiss
blood
higher
hepat
c
viru
significantli
higher
viral
load
like
hiv
hepat
c
viru
rna
viru
typic
integr
host
dna
hepat
c
viru
belong
flaviviru
group
singlestrand
envelop
rna
virus
replic
mutat
rate
hepat
c
viru
much
higher
hiv
hepat
c
viru
infect
selfclear
case
clear
viru
may
becom
latent
activ
later
time
treatment
acut
hepat
c
reduc
risk
chronic
infect
individu
infect
hepat
c
viru
high
risk
develop
liver
cirrhosi
upon
infect
hepat
viru
hepat
b
viru
vaccin
hepat
viru
hepat
b
viru
individu
chronic
hepat
c
viru
infect
therefor
advis
liver
cirrhosi
caus
chronic
hepat
c
viru
infect
may
lead
liver
failur
cancer
hepat
c
viru
infect
cure
exist
multipl
genotyp
complic
therapeut
approach
current
cost
extrem
high
order
current
six
genotyp
differ
geograph
distribut
known
usa
genotyp
common
hiv
infect
believ
increas
rate
progress
hepat
c
diseas
therefor
recommend
individu
confirm
hiv
infect
also
test
hepat
c
viru
howev
impact
hepat
c
viru
infect
hiv
diseas
progress
signific
screen
hepat
c
viru
infect
initi
perform
rapid
antibodi
test
deliv
result
within
min
recent
oraquick
hepat
c
viru
rapid
antibodi
test
approv
fda
use
fingerstick
blood
like
saliva
test
made
avail
near
futur
antibodi
test
distinguish
current
previou
infect
therefor
confirmatori
test
need
screen
test
posit
histor
immunoblot
assay
use
confirm
infect
test
hepat
c
viru
rna
current
method
choic
strong
correl
serum
salivari
antibodi
level
hepat
c
viru
infect
report
sinc
one
first
studi
success
demonstr
antihepat
c
viru
antibodi
saliva
publish
sinc
rapid
test
use
saliva
evolv
rapid
test
requir
min
sampl
result
latter
lowcomplex
userfriendli
test
built
platform
oraquick
advanc
rapid
test
although
hepat
c
viru
test
devic
may
becom
fda
approv
determin
presenc
antibodi
oral
sampl
futur
confirmatori
test
determin
activ
infect
still
need
hepat
c
viru
transmiss
requir
bloodblood
contact
propos
salivabas
diagnost
might
safer
blood
test
infecti
hepat
c
viru
saliva
observ
gener
individu
periodont
diseas
gingiv
serum
viral
load
higher
virionsml
infect
salivari
contact
unlik
fulli
exclud
hiv
contain
two
separ
ident
strand
rna
upon
infect
transcrib
dna
enter
nucleu
integr
human
genom
occur
infect
cell
produc
viral
particl
infect
new
cell
viru
target
thelper
cell
cell
immun
system
therebi
affect
cellmedi
immun
make
individu
progress
vulner
opportunist
infect
aidsrel
cancer
upon
integr
viral
dna
human
genom
infect
clear
remain
lifelong
stillunknown
reservoir
patient
surviv
block
progress
fullblown
aid
complianc
strict
drug
regim
need
follow
suppress
viru
product
continu
infect
new
cell
earli
hiv
infect
easili
diagnos
symptom
resembl
influenza
individu
awar
risk
hiv
infect
may
request
hiv
test
howev
antibodi
test
demonstr
hiv
infect
seroconvers
take
week
recent
infect
requir
anoth
approach
best
way
demonstr
earli
infect
nucleic
acid
amplif
depend
risk
factor
postexposur
prophylaxi
healthcar
worker
individu
suspect
exposur
hiv
eg
unprotect
sexual
contact
use
contamin
needl
consid
case
healthcar
worker
postexposur
prophylaxi
individu
remain
alert
sever
week
potenti
sign
hiv
infect
preexposur
prophylaxi
antiretrovir
drug
demonstr
reduc
risk
infect
individu
involv
highrisk
behavior
wwwcdcgovhivpreventionresearchprep
mani
case
hiv
infect
initi
go
unnot
individu
medic
consult
relat
secondari
opportunist
infect
usual
point
individu
past
hiv
seroconvers
window
infect
identifi
rapid
antibodi
screen
test
hiv
infect
curabl
highli
like
person
antibodi
hiv
infect
confirmatori
test
valid
antibodi
test
result
requir
exclud
falseposit
result
patient
wait
period
week
get
final
test
result
difficult
psycholog
reason
pointofcar
devic
use
diagnos
valid
hiv
infect
within
h
import
devic
also
abl
determin
accur
viral
load
counsel
could
includ
concomitantli
immedi
start
appropri
antiretrovir
therapi
would
also
reduc
number
individu
requir
return
clinic
receiv
confirmatori
test
result
may
thu
decreas
transmiss
viru
fourthgener
immunoassay
detect
antigen
antihiv
immunoglobulin
develop
readili
avail
pointofcar
set
combin
nucleic
acid
antibodi
detect
better
option
result
avail
nucleic
acidamplif
method
achiev
desir
sensit
also
allow
detect
earli
infect
seroconvers
ultim
pointofcar
devic
allow
detect
antihiv
immunoglobulin
viral
antigen
eg
solubl
viral
rna
well
provir
dna
type
devic
provid
screen
confirm
infect
within
seroconvers
window
presenc
viral
rna
could
confirm
either
presenc
viral
antigen
provir
dna
note
detect
antihiv
immunoglobulin
simplest
method
screen
hiv
infect
howev
neonat
hivinfect
mother
carri
matern
antihiv
immunoglobulin
year
whilst
infect
three
main
transmiss
rout
hiv
infect
unprotect
sexual
intercours
use
contamin
needl
transmiss
mother
child
pregnanc
birth
breastfeed
role
saliva
diagnosi
inhibit
hiv
wide
discuss
topic
review
see
pageshaf
et
al
shiboski
et
al
presenc
viabl
hiv
particl
saliva
controversi
detect
hiv
nucleic
acid
saliva
demonstr
clear
whether
viral
rna
detect
deriv
viabl
viral
particl
instead
repres
free
nucleic
acid
fragment
gener
viral
load
saliva
lower
correspond
blood
sampl
occasion
high
secretor
hiv
report
perhap
indic
presenc
reservoir
hiv
salivari
gland
oropharyng
tissu
infect
lymphocyt
variou
oral
sourc
possibl
sourc
hiv
viral
hypersecretor
import
recogn
presenc
reservoir
potenti
sourc
transmiss
thousandfold
higher
viral
rna
level
report
tonsil
biopsi
correspond
blood
sampl
even
remark
detect
hiv
copi
per
ml
parotid
cyst
aspir
individu
undetect
blood
viremia
although
presenc
reservoir
acknowledg
exist
hiv
epitheli
cell
buccal
mucosa
demonstr
saliva
regard
relev
transmiss
rout
saliva
lyse
hiv
particl
vitro
hypoton
mani
salivari
protein
demonstr
inhibit
hiv
infect
vitro
includ
lysozym
cysteinerich
defensin
lactoferrin
secretori
leukocyt
proteas
inhibitor
salivari
agglutinin
oral
caviti
solubl
thought
inactiv
hiv
mechan
involv
bind
hiv
glycoprotein
expos
hiv
envelop
oral
caviti
major
site
infect
transmiss
virus
innat
immun
system
present
mouth
prevent
infect
eg
hiv
wherea
virus
includ
rabi
herp
simplex
viru
epsteinbarr
viru
infect
transmit
oral
particular
import
defens
antibodi
bacteri
viral
pathogen
detect
use
saliva
swab
oral
mucosa
frequenc
oralbas
test
viral
bacteri
diseas
increas
commerci
entiti
becom
involv
new
product
develop
major
advantag
oralbas
test
cost
patient
accept
equival
blood
test
possibl
home
test
whether
increas
test
viral
infect
recommend
depend
sever
factor
cost
extrem
import
inexpens
rapid
saliva
diagnost
use
dental
offic
provid
screen
test
mani
viral
diseas
includ
hiv
hepat
c
viru
influenzain
fact
situat
bloodbas
antibodi
test
perform
moreov
oral
symptom
suggest
request
patient
dentist
could
conveni
initi
viral
nucleic
acidbas
test
collect
appropri
oral
sampl
send
central
laboratori
analysi
inform
patient
physician
follow
altern
rapid
oral
antibodi
test
could
perform
dentist
offic
screen
result
reactiv
patient
refer
immedi
clinic
confirmatori
test
scientif
literatur
indic
sever
commerci
assay
may
suitabl
use
oral
sampl
sever
research
laboratori
develop
oral
fluidbas
test
infecti
diseas
sever
noninfecti
system
diseas
special
attent
requir
assay
perform
home
individu
involv
diseas
potenti
great
social
impact
eg
hiv
patient
may
alway
act
appropri
upon
receiv
test
result
larg
number
individu
visit
dentist
annual
health
profession
screen
viral
infect
dental
offic
follow
referr
physician
could
major
impact
control
transmiss
symptom
infecti
diseas
select
ship
pair
saliva
serum
sampl
wih
cohort
collect
bronx
manhattan
wih
fund
nation
institut
allergi
infecti
diseas
cofund
nation
cancer
institut
cheryl
barber
nyu
acknowledg
organ
collect
bank
collect
sampl
bank
develop
valid
ucplf
antibodi
assay
perform
part
financi
support
us
nation
institut
health
grant
